|Title:||Use of QuantiFERON-TB Gold In-tube assay in screening for neutralizing anti-interferon-γ autoantibodies in patients with disseminated nontuberculous mycobacterial infection||Authors:||Wu, U-I
|Keywords:||Anti-IFN-γautoantibodies; Clinical utility; Disseminated NTM infections; IGRA; QuantiFERON; Adult; Aged; Antibodies, Neutralizing; Autoantibodies; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Humans; Interferon-gamma; Interferon-gamma Release Tests; Male; Middle Aged; Mycobacterium Infections, Nontuberculous||Issue Date:||Feb-2018||Publisher:||ELSEVIER SCI LTD||Source:||Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases||Abstract:||
Anti-interferon- γ (IFN-γ) autoantibodies (anti-IFN-γ Abs) have been increasingly recognized as an important cause of disseminated nontuberculous mycobacterial (DNTM) infection, and identification of this immunodeficiency impacts clinical management. However, the protean disease manifestations and inaccessibility to diagnostic tests in clinical settings hamper its early diagnosis. Here, we sought to determine whether QuantiFERON-TB Gold In-tube (QFT-GIT), a commercialized IFN-γ release assay, could be used to screen for neutralizing anti-IFN-γ Abs among previously healthy adults with DNTM infection.
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.